RxDoctor Payments Data

Pamela Warren, MD

Family Medicine · Cedar Park, TXNPI 1871602615

Payments from drug & device makers

$4,928in general payments, 2019–2025

Across 184 payments — averaging $26.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$3K
  • AbbVie$835
  • Boehringer Ingelheim$340
  • Novo Nordisk$244
  • Lilly USA, LLC$183
  • Pfizer$172
  • plus $432 from 7 others

What the payments were for

  • Food & beverage$4,88499%
  • Education$441%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,928 in reported general payments places this provider in the 85th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$67,970
Medicare patients
130
Services billed
1,033

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide51$79,373
OzempicSemaglutide22$24,647
FarxigaDapagliflozin Propanediol26$23,077
JardianceEmpagliflozin14$17,723
SynthroidLevothyroxine Sodium54$3,413
Levothyroxine Sodium128$1,627
Armour ThyroidThyroid,pork12$1,484
Escitalopram Oxalate99$1,105
Metformin Hcl ErMetformin Hcl80$1,039
Nebivolol Hcl20$1,031
Albuterol Sulfate HfaAlbuterol Sulfate43$978
Rosuvastatin Calcium70$858
Atorvastatin Calcium109$763
Estradiol12$654
Amlodipine Besylate90$651

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$183$79,37351 claims
Novo NordiskOzempic$244$24,64722 claims
AstraZenecaFarxiga$2,723$23,07726 claims
Boehringer IngelheimJardiance$340$17,72314 claims
AbbVieSynthroid, Armour Thyroid$835$4,89766 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Cedar Park

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →